戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1                     Receptors of the insulin/insulinlike growth factor (IGF) family have been implica
2 f-function (rf) mutants of daf-2, an insulin/insulinlike growth factor (IGF) receptor (INR) homolog g
3 factor (HGF), epidermal growth factor (EGF), insulinlike growth factor (IGF)-1, tumor necrosis factor
4 The authors examined the interaction between insulinlike growth factor (IGF)-1, vascular endothelial
5  and tumor targeting ability of radiolabeled insulinlike growth factor (IGF)-I.
6                                              Insulinlike growth factor 1 (IGF-1) also failed to dimin
7   Neither exogenous interleukin-6 (IL-6) nor insulinlike growth factor 1 (IGF-1) overcomes Perifosine
8 ebo titrated to the upper quartile of normal insulinlike growth factor 1 (IGF-1) range for 18 months.
9 tiation and fiber type specificity due to an insulinlike growth factor 1 (IGF-1)-calcineurin-NFAT sig
10 e in granulocyte IGF-IR expression and serum insulinlike growth factor 1 accumulation at high doses,
11                                              Insulinlike growth factor 1 levels were significantly lo
12 tio, 5.33 [95% CI, 0.97-29.30]; P = .06) and insulinlike growth factor 1 receptor (hazard ratio, 2.74
13 T to monitor therapy with an antibody to the insulinlike growth factor 1 receptor (IGF-1R antibody) i
14 , and pharmacodynamic properties of the anti-insulinlike growth factor 1 receptor (IGF-IR) monoclonal
15              Expressions of beta-catenin and insulinlike growth factor 1 receptor were associated wit
16  glucose), growth factors (e.g., insulin and insulinlike growth factor 1), hormones (e.g., leptin), a
17 5% CI, 0.51-0.63) for WINROP (Weight, IGF-1 [insulinlike growth factor 1], Neonatal, ROP), 1.00 (95%
18 ified calgranulin B and a unique fragment of insulinlike growth factor binding protein 1, which were
19 hibitor of metalloproteinases 2 (TIMP-2) and insulinlike growth factor binding protein 7 (IGFBP7) cou
20  a linear survival signaling cascade used by insulinlike growth factor I (IGF-I) that consists of the
21  in prostate cancer involves upregulation of insulinlike growth factor type 1 receptor (IGF-1R).
22 ropoietin, transforming growth factor beta1, insulinlike growth factor type 1, angiopoietin 1, angiop
23 ctor [VEGF], hepatocyte growth factor [HGF], insulinlike growth factor-1 [IGF-1], and thrombopoietin
24   IMiDs also block the stimulatory effect of insulinlike growth factor-1 on NF-kappa B activity and p
25 ancer growth regulation, we exposed cells to insulinlike growth factor-1 or transferrin, which increa
26 roid-stimulating hormone receptor (TSHR) and insulinlike growth factor-1 receptor (IGF-1R).
27                                          The insulinlike growth factor-1 receptor is a potentially im
28 rug-resistance conferred by interleukin-6 or insulinlike growth factor-1.
29 talloproteinase 1 and 2 (TIMP-1 and TIMP-2), insulinlike growth factor-binding protein 2 (IGFBP-2), n
30 nificantly attenuated the release of urinary insulinlike growth factor-binding protein 7 and tissue i
31                   In multiple myeloma cells, insulinlike growth factor-I (IGF-I) activates 2 distinct
32 6), tumor necrosis factor-alpha (TNF-alpha), insulinlike growth factor-I (IGF-I), and IGF binding pro
33 ful growth mediators like growth hormone and insulinlike growth factor-I.
34  pathway, closely related to the insulin and insulinlike growth factor-signaling pathways of mammals,
35                                              Insulinlike signaling in neurons alone was sufficient to
36                                           An insulinlike signaling pathway controls Caenorhabditis el